News Column

Data on Optical Coherence Tomography Reported by J. Urban and Co-Researchers (Optical Coherence Tomography Imaging of Erythematotelangiectatic...

August 15, 2014



Data on Optical Coherence Tomography Reported by J. Urban and Co-Researchers (Optical Coherence Tomography Imaging of Erythematotelangiectatic Rosacea During Treatment With Brimonidine Topical Gel 0.33%: A Potential Method for Treatment Outcome ...)

By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Optical Coherence Tomography is the subject of a report. According to news reporting from Kent, United Kingdom, by NewsRx journalists, research stated, "Patients with moderate to severe rosacea often seek treatment to reduce erythema and vascular markings. Few studies have looked at the effectiveness of the novel treatment, brimonidine topical gel 0.33%, trademark name Mirvaso , in the treatment of rosacea."

The news correspondents obtained a quote from the research, "We report the use of optical coherence tomography (OCT) scanning to monitor the effectiveness of Mirvaso on in vivo skin. OCT is a non-invasive optical imaging technique that can provide high-resolution imaging of vessel and cellular morphology. OCT may be useful as a pre-treatment assessment tool for identifying possible morphologic features in the skin that may serve as outcome predictors. OCT may also serve as a monitoring tool in the treatment of rosacea. To examine and describe how OCT skin morphology changes when exposed to brimonidine topical gel 0.33% in the treatment of erythematotelangiectatic rosacea. Normal in vivo telangiectasias and erythematous patches and papules were examined prior to treatment clinically, dermatoscopically, and through OCT scans. Brimonidine topical gel 0.33% was applied to the face and OCT images were acquired at defined time intervals: baseline; immediately (

According to the news reporters, the research concluded: "This technology could potentially be used for the non-invasive in vivo monitoring of other topical treatments."

For more information on this research see: Optical Coherence Tomography Imaging of Erythematotelangiectatic Rosacea During Treatment With Brimonidine Topical Gel 0.33%: A Potential Method for Treatment Outcome Assessment. Journal of Drugs in Dermatology, 2014;13(7):821-826. Journal of Drugs in Dermatology can be contacted at: Journal Of Drugs In Dermatology, 377 Park Ave South, 6TH Floor, New York, NY 10016, USA (see also Optical Coherence Tomography).

Our news journalists report that additional information may be obtained by contacting J. Urban, Michelson Diagnost Ltd, Orpington, Kent, United Kingdom. Additional authors for this research include A.H. Siripunvarapon, A. Meekings, A. Kalowitz and O. Markowitz.

Keywords for this news article include: Kent, Europe, Erythema, Skin Diseases, United Kingdom, Imaging Technology, Optical Coherence Tomography, Skin and Connective Tissue Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters